Avalo Therapeutics

What Avalo Therapeutics does

Avalo Therapeutics (NASDAQ: AVTX) is a clinical-stage biopharmaceutical company headquartered in Wayne, Pennsylvania, focused entirely on developing therapeutics that target the IL-1β pathway for immune-mediated inflammatory diseases. The company was formed through the February 2020 merger of Avalo Therapeutics with Aevi Genomic Medicine and is led by CEO Garry A. Neil, MD (former Group President of J&J Pharmaceutical R&D) with a team drawn from J&J, Merck, AstraZeneca, Biogen, CSL Behring, and other major pharmaceutical companies.

The company's pipeline centers on two anti-IL-1β monoclonal antibodies: (1) Abdakibart (AVTX-009), a high-affinity humanized IgG mAb acquired via the March 2024 purchase of AlmataBio for $42.5 million, which delivered positive Phase 2 LOTUS topline results in May 2026 in 253 adults with moderate-to-severe hidradenitis suppurativa (HiSCR75 response rates of 42.2% at 150mg and 42.9% at 300mg versus 25.6% placebo, p<0.05), positioning it for registrational Phase 3 development; and (2) AVTX-010, a long-acting next-generation anti-IL-1β antibody designed to extend dosing intervals, with an IND filing planned for H1 2027. Avalo is also exploring additional inflammatory indications beyond HS.

As a clinical-stage company with no approved products, Avalo generates no product revenue. Its capital structure is funded entirely through equity offerings — $31.5M (2021), $15M (2023), $185M private placement (2024), and $375M public offering (May 2026) — yielding a pro forma cash position of $450–470M and runway into 2028. The company is building commercial infrastructure (global marketing, specialty distribution channels, dermatology launch leadership) in preparation for potential first commercial launch. Analyst coverage from Guggenheim, Citizens, Wolfe, HC Wainwright, BTIG, and TD Cowen shows Buy/Outperform ratings with price targets of $40–52, and Avalo was added to the Russell 2000 and Russell 3000 indexes in June 2026.

Name

Avalo Therapeutics

Legal name

Avalo Therapeutics, Inc.

Website

https://avalotx.com

Company type

Public

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Avalo Therapeutics (NASDAQ: AVTX) is a clinical-stage biopharmaceutical company developing anti-IL-1β monoclonal antibodies for immune-mediated inflammatory diseases, with lead asset abdakibart (AVTX-009) advancing to Phase 3 following positive Phase 2 LOTUS results in hidradenitis suppurativa.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

akta.pro secondary industry

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

Keywords

• IL-1β therapeutics
• Monoclonal antibody development
• Inflammatory disease treatment
• Clinical-stage biopharmaceuticals
• Immune-mediated disease therapies

Headquarters

HQ city

Rockville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue clinical stage biotechnology company. Expected to generate revenue through commercial sales of therapeutic products (abdakibart and pipeline candidates) upon regulatory approval. Revenue model will be based on prescription drug sales through distribution channels to healthcare providers and patients.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

Avalo Therapeutics is a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics that specifically target the IL-1β pathway to treat immune-mediated inflammatory diseases. Its lead asset, abdakibart (AVTX-009), is an anti-IL-1β monoclonal antibody in Phase 2/3 development for hidradenitis suppurativa, and its second program, AVTX-010, is a long-acting next-generation anti-IL-1β antibody in preclinical development with IND filing planned for H1 2027.

Product overview

Avalo Therapeutics is a clinical-stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. The company's product portfolio consists of two drug candidates: (1) Abdakibart (AVTX-009), a high-affinity anti-IL-1β monoclonal antibody that recently completed Phase 2 development for hidradenitis suppurativa and demonstrated positive topline results, positioning it for Phase 3 advancement; and (2) AVTX-010, a long-acting next-generation anti-IL-1β antibody designed to extend dosing intervals, with IND filing planned for H1 2027. Both products target the IL-1β pathway, which is a central driver of inflammatory processes in immune-mediated diseases.

Differentiator

Problem solved

Functional benefit

Brands

• Abdakibart (AVTX-009): High affinity, highly potent humanized IgG monoclonal antibody designed to specifically inhibit IL-1β and block downstream inflammatory pathways. Currently being studied as a treatment for hidradenitis suppurativa.
• AVTX-010

Products and services

• Abdakibart (AVTX-009) Investigational high affinity, highly potent humanized IgG monoclonal antibody designed to specifically inhibit IL-1β and block downstream inflammatory pathways; being studied as a treatment for moderate-to-severe hidradenitis suppurativa in the Phase 2 LOTUS trial and intended for additional immune-mediated inflammatory indications. Intended for patients with chronic inflammatory skin disease and the physicians who treat them.
• AVTX-010 Long-acting next-generation anti-IL-1β monoclonal antibody designed to extend dosing intervals and build upon the differentiated profile established by abdakibart. In development for hidradenitis suppurativa and additional inflammatory disorders, with IND filing planned for the first half of 2027.

Quantifiable outcome

• 42.2% and 42.9% HiSCR75 response rates for 150mg and 300mg doses respectively (p<0.05) vs 25.6% placebo in Phase 2 LOTUS trial
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• AlmataBio, Inc.coreStrategic or Co-development Partner · 29 March 2024Avalo acquired AlmataBio, Inc. for $42.5 million to obtain AVTX-009, a Phase 2 ready anti-IL-1β monoclonal antibody. This acquisition was the primary mechanism for obtaining the company's lead clinical asset and represents a core strategic transaction.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• MoonLake Immunotherapeutics: Clinical-stage immunology biotech developing sonelokimab, an IL-17A/F nanobody with positive Phase 2 data in hidradenitis suppurativa. Closest direct competitor to Avalo in HS with similar stage and indication focus.
• AnaptysBio: Clinical-stage immunology biotech developing IL-36R antagonist (imsidolimab) and other antibodies for inflammatory diseases including HS. Comparable in stage, therapeutic area, and monoclonal antibody modality.

Broad incumbents

• UCB: Approved bimekizumab (Bimzelx) for HS — a direct competitive biologic. Large-cap immunology incumbent with established commercial infrastructure in dermatology and rheumatology that Avalo will need to compete against.
• Novartis: Approved secukinumab (Cosentyx) for HS. Major pharma with established IL-17 franchise, dermatology commercial footprint, and global payer relationships that create competitive pressure on emerging HS entrants.
• AbbVie: Developer of lutikizumab (anti-IL-1α/1β) for HS and originator of Humira (adalimumab), the first HS biologic. Most direct large-cap competitive threat given lutikizumab's IL-1 pathway overlap with abdakibart.

Emerging players

• Union Therapeutics: Clinical-stage biotech developing oral and topical therapies for HS and other inflammatory skin diseases. Comparable as a smaller dermatology-focused emerging player addressing the same patient population.
• Aclaris Therapeutics: Clinical-stage biotech with immunology and dermatology pipeline. Comparable in size, stage, and therapeutic focus; some leadership overlap (Avalo SVP Regulatory previously led regulatory at Aclaris).
• RAPT Therapeutics: Clinical-stage immunology biotech developing small molecules and antibodies for inflammatory diseases. Comparable as a small-cap public biotech focused on inflammation with similar funding profile.
• Kymera Therapeutics: Clinical-stage biotech developing immunology and oncology therapeutics with targeted protein degradation platform. Comparable as a small-cap public biotech with focused inflammatory disease pipeline.

Others

• Chemocentryx (acquired by Amgen): Recently acquired small-cap immunology biotech — useful analog for how larger pharma acquires late-stage inflammation companies with single lead assets, relevant to Avalo's potential strategic exit.

Market position

Weaknesses1 record

Competitive moat4 records

Key risks1 record

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/avalotx
• Xx.com/Avalotx

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avalo Therapeutics